CSF3 and idiopathic pulmonary fibrosis: To evaluate the therapeutic potential of neutralizing CSF3 in pulmonary fibrosis, we developed a CSF3-neutralizing antibody, FB-101, and assessed its efficacy in two distinct BLM-induced IPF mouse models.